Design, synthesis and biological evaluation of 3,5-diaryl-isoxazoline/ isoxazole-pyrrolobenzodiazepine conjugates as potential anticancer agents

European Journal of Medicinal Chemistry

Volumn 45, Issue 9, 2010, Pages 3924-3937

  Kamal, Ahmed ^a   Surendranadha Reddy, J ^a   Janaki Ramaiah, M ^a   Dastagiri, D ^a   Vijaya Bharathi, E ^a   Ameruddin Azhar, M ^a   Sultana, Farheen ^a   Pushpavalli, S N C V L ^a   Pal Bhadra, Manika ^a   Juvekar, Aarti ^b   Sen, Subrata ^b   Zingde, Surekha ^b  

^a INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^b Research and Education in Cancer   (India)

Author keywords

3,5 Diaryl isoxazoline isoxazole; Cytochrome c; p53; Procaspase 3; Pyrrolobenzodiazepine

Indexed keywords

1,2,3,11A TETRAHYDRO 8 HYDROXY 7 METHOXY 5H PYRROLO[2,1 C][1,4]BENZODIAZEPIN 5 ONE; 7 METHOXY 8 [3 [[2 METHOXY 5 [3 (3,4,5 TRIMETHOXYPHENYL) 4,5 DIHYDRO 5 ISOXAZOLYLPHENYL]OXY]PROPYLOXY] 1,2,3,11A TETRAHYDRO 5H PYRROLO[2,1 C][1,4]BENZODIAZEPINE 5 ONE; 7 METHOXY 8 [3 [[2,6 DIMETHOXY 4 [5 (3,4,5 TRIMETHOXYPHENYL) 3 ISOXAZOLYLPHENYL]OXY]PROPYLOXY] 1,2,3,11A TETRAHYDRO 5H PYRROLO[2,1 C][1,4]BENZODIAZEPINE 5 ONE; 7 METHOXY 8 [4 [[2 METHOXY 5 [3 (3,4,5 TRIMETHOXYPHENYL) 4,5 DIHYDRO 5 ISOXAZOLYLPHENYL]OXY]BUTYLOXY] 1,2,3,11A TETRAHYDRO 5H PYRROLO[2,1 C][1,4]BENZODIAZEPINE 5 ONE; 7 METHOXY 8 [4 [[2,6 DIMETHOXY 4 [3 (2,3,4 TRIMETHOXYPHENYL) 4,5 DIHYDRO-5 ISOXAZOLYLPHENYL]OXYBUTYLOXY] 1,2,3,11A TETRAHYDRO 5H PYRROLO[2,1 C][1,4]BENZODIAZEPINE 5 ONE; 7 METHOXY 8 [5 [[2 METHOXY 4 [5 (3,4,5 TRIMETHOXYPHENYL) 4,5 DIHYDRO 3 ISOXAZOLYLPHENYL]OXY]PENTYLOXY] 1,2,3,11A TETRAHYDRO 5H PYRROLO[2,1 C][1,4]BENZODIAZEPINE 5 ONE; 7 METHOXY 8 [5 [[2 METHOXY 5 [3 (3,4,5 TRIMETHOXYPHENYL) 4,5 DIHYDRO 5 ISOXAZOLYLPHENYL]OXY]PENTYLOXY] 1,2,3,11A TETRAHYDRO 5H PYRROLO[2,1 C][1,4]BENZODIAZEPINE 5 ONE; 7 METHOXY 8 [5 [[2,6 DIMETHOXY 4 [3 (2,3,4 TRIMETHOXYPHENYL) 4,5 DIHYDRO 5 ISOXAZOLYLPHENYL]OXYPENTYLOXY] 1,2,3,11A TETRAHYDRO 5H PYRROLO[2,1 C][1,4]BENZODIAZEPINE 5 ONE; 7 METHOXY 8 {3 [(2 METHOXY 4 (5 [3,4,5 TRIMETHOXYPHENYL] 4,5 DIHYDRO 3 ISOXAZOLYLPHENYL)OXY]PROPYLOXY} 1,2,3,11A TETRAHYDRO 5H PYRROLO[2,1 C][1,4]BENZODIAZEPINE 5 ONE; 7 METHOXY 8 {4 [(2 METHOXY 4 (5 [3,4,5 TRIMETHOXYPHENYL] 4,5 DIHYDRO 3 ISOXAZOLYLPHENYL)OXY]BUTYLOXY} 1,2,3,11A TETRAHYDRO 5H PYRROLO[2,1 C][1,4]BENZODIAZEPINE 5 ONE; 7 METHYLOXY 8 [3 [[2 METHOXY 5 [5 (3,4,5 TRIMETHOXYPHENYL) 3 ISOXAZOLYLPHENYL]OXY]PROPYLOXY] 1,2,3,11A TETRAHYDRO 5H PYRROLO[2,1-C][1,4]BENZODIAZEPINE 5 ONE; 7 METHYLOXY 8 [4 [[2 METHOXY 5 [5 (3,4,5 TRIMETHOXYPHENYL) 3 ISOXAZOLYLPHENYL]XY]BUTYLOXY]1,2,3,11A TETRAHYDRO 5H PYRROLO[2,1 C][1,4]BENZODIAZEPINE 5 ONE; 7 METHYLOXY 8 [5 [[2 METHOXY 5 [5 (3,4,5 TRIMETHOXYPHENYL) 3 ISOXAZOLYLPHENYL]OXY]PENTYLOXY] 1,2,3,11A TETRAHYDRO 5H PYRROLO[2,1 C][1,4]BENZODIAZEPINE 5 ONE; ANTINEOPLASTIC AGENT; CASPASE 3; CYTOCHROME C; DOXORUBICIN; ISOXAZOLINE DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN P53; PYRROLO[2,1 C][1,4]BENZODIAZEPINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; COLON CANCER; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME RELEASE; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; LEUKEMIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; MITOCHONDRION; MOUTH CANCER; OVARY CANCER; PROSTATE CANCER; UTERINE CERVIX CANCER;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZODIAZEPINES; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DESIGN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITORY CONCENTRATION 50; ISOXAZOLES;

EID: 77955559364     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2010.05.047     Document Type: Article

References (34)

1. R. Morphy, and Z. Rankovic J. Med. Chem. 48 2005 6523 6543
2. R. Morphy, C. Kay, and Z. Rankovic Drug Discov. Today 9 2004 641 651
3. A.B. Alexis, J.E. Peter, W.H. Nicole, S.L. Margaret, E.R. Joseph Leha' r, S. George, R.Z. Grant, A.F. Michael, R.S. Brent, and T.K. Curtis PNAS 100 2000 7977 7982
4. B. Meunier Acc. Chem. Res. 41 2008 69 77
5. G.R. Pettit, G.M. Cragg, and S.B. Singh J. Nat. Prod. 50 1987 386 391
6. C.M. Lin, H.H. Ho, and G.R. Pettit Biochemistry 28 1989 6984 6991
7. L. Wang, K.W. Woods, Q. Li, K.J. Barr, R.W. McCroskey, S.M. Hannick, L. Gherke, R.B. Credo, Y.A. Hui, K. Marsh, R. Warner, J.Y. Lee, N. ZielinskiMozng, D. Frost, S.H. Rosenberg, and H.L. Sham J. Med. Chem. 45 2002 1697 1711
8. K. Ohsumi, T. Hatanaka, K. Fujita, R. Nakagawa, Y. Fukuda, Y. Nihei, Y. Suga, Y. Morinaga, Y. Akiyama, and T. Tsuji Bioorg. Med. Chem. Lett. 8 1998 3153 3158
9. N.H. Nam, Y. Kim, Y.J. You, D.H. Hong, H.M. Kim, and B.Z. Ahn Bioorg. Med. Chem. Lett. 11 2001 3073 3076
10. D. Simoni, G. Grisolia, G. Giannini, M. Roberti, R. Rondanin, L. Piccagli, R. Baruchello, M. Rossi, R. Romagnoli, F.P. Invidiata, S. Grimaudo, M.K. Jung, E. Hamel, N. Gebbia, L. Crosta, V. Abbadessa, A. DiCristina, L. Dusonchet, M. Meli, and M. Tolomeo J. Med. Chem. 48 2005 723 736
11. J. Kaffy, R. Pontiks, D. Carrez, A. Croisy, C. Monnereta, and J.C. Floreta Bioorg. Med. Chem. 14 2006 4067 4077
12. D.E. Thurston Molecular Aspects of Anticancer Drug-DNA Interactions 1993 The Macmillan Press Ltd. London, UK pp. 54-88
13. R.L. Petrusek, E.L. Uhlenhopp, N. Duteau, and L.H. Hurley J. Biol. Chem. 257 1982 6207 6216
14. L.H. Hurley, T. Reck, D.E. Thurston, D.R. Langley, K.G. Holden, R.P. Hertzberg, J.R.E. Hoover, G.J. Gallagher, L.F. Faucette, S.M. Mong, and R.K. Johnson Chem. Res. Toxicol. 1 1988 258 268
15. S.C. Wilson, P.W. Howard, S.M. Forrow, J.A. Hartley, L.J. Adams, T.C. Jenkins, L.R. Kelland, and D.E. Thurston J. Med. Chem. 42 1999 4028 4041
16. M. Tercel, S.M. Stribbling, H. Sheppard, B.G. Siim, K. Wu, S.M. Pullen, K.J. Botting, W.R. Wilson, and W.A. Denny J. Med. Chem. 46 2003 2132 2151
17. P.G. Baraldi, G. Balboni, B. Cacciari, A. Guiotto, S. Manfredini, R. Romagnoli, G. Spalluto, D.E. Thurston, P.W. Howard, N. Bianchi, C. Rutigiiano, C. Mischiati, and R. Gambari J. Med. Chem. 42 1999 5131 5141
18. Y. Damayanthi, B.S.P. Reddy, and J.W. Lown J. Org. Chem. 64 1999 290 292
19. J.J. Wang, Y.K. Shen, W.P. Hu, M.C. Hsieh, F.L. Lin, M.K. Hsu, and M.H. Hsu J. Med. Chem. 49 2006 1442 1449
20. A. Kamal, E. Laxman, and P.S.M.M. Reddy Tetrahedron Lett. 41 2000 7743 7746
21. A. Kamal, N. Shankaraiah, V. Devaiah, and K.L. Reddy Tetrahedron Lett. 47 2006 6553 6556
22. A. Kamal, G. Ramesh, N. Laxman, P. Ramulu, O. Srinivas, K. Neelima, A.K. Kondapi, V.B. Srinu, and H.M. Nagarajaram J. Med. Chem. 45 2002 4679 4688
23. A. Kamal, R. Ramu, T. Venkatesh, G.B. Ramesh Khanna, M.S. Barkume, A. Juvekar, and S. Zingde Bioorg. Med. Chem. 15 2007 6868 6875
24. A. Kamal, M.N. Khan, Y.V.V. Srikanth, K.S. Reddy, A. Juvekar, S. Sen, N. Kurian, and S. Zingde Bioorg. Med. Chem. 16 2008 7804 7810
25. A. Kamal, N. Shankaraiah, V. Devaiah, K.L. Reddy, A. Juvekar, S. Sen, N. Kurian, and S. Zingde Bioorg. Med. Chem. Lett. 18 2008 1468 1473
26. A. Kamal, P.P. Kumar, B.N. Seshadri, O. Srinivas, M.S. Kumar, S. Sen, N. Kurian, A. Juvekar, and S. Zingde Bioorg. Med. Chem. 16 2008 3895 3906
27. A. Kamal, E.V. Bharathi, M.J. Ramaiah, D. Dastagiri, J.S. Reddy, A. Viswanath, F. Sultana, S.N.C.V.L. Pushpavalli, M.P. Bhadra, H.K. Srivastava, G.N. Sastry, A. Juvekar, S. Sen, and S. Zingde Bioorg. Med. Chem. 18 2010 526 542
28. A. Kamal, K. Sreekanth, P.P. Kumar, N. Shankaraiah, G. Balakishan, M.J. Ramaiah, S.N.C.V.L. Pushpavalli, P. Ray, and M.P. Bhadra Eur. J. Med. Chem. 45 2010 2173 2181
29. T. Taguchi, Y. Kato, Y. Baba, G. Nishimura, Y. Tanigaki, C. Horiuchi, I. Mochmatsu, and M. Tsukuda Oncol. Rep. 11 2004 421 426
30. X. Wang, and X. Jiang Ann. Rev. Biochem. 3 2004 87 106
31. R.M. Kluck, E.B. Wetzel, D.R. Green, and D.D. Newmeyer Science 275 1997 1132 1136
32. W.P. Hu, H.S. Yu, P.J. Sung, F.Y. Tsai, Y.K. Shen, L.S. Chang, and J.J. Wang Chem. Res. Toxicol. 20 2007 905 912
33. L. Tyas, V.A. Brophy, A. Pope, J.A. Rivett, and J.M. Tavare EMBO Rep. 3 2000 266 270
34. B.A. Carlson, M.M. Dubay, E.A. Sausville, L. Brizuela, and P.J. Worland Cancer Res. 56 1996 2973 2978